**VITAMIN D LEVEL IN RHEUMATOID ARTHRITIS PATIENTS IN SAUDI ARABIA AND ITS CORRELATION WITH DISEASE ACTIVITY AND MOOD CHANGES**

Noha Maher Abdelnaser 1, Shaza Abdul Basset Abdul Basset 2, Hanan Abdelaziz Mahdy3, Rasha M. Soubhy Elkhouly4, , Ahmed A.G.Ibrahim5

1-Department of rheumatology, rehabilitation and physical medicine, Benha University, Egypt

2-Department of rheumatology, rehabilitation and physical medicine, Benha University, Egypt

3-Department of internal medicine, Ain Shams University, Egypt

4-Department of psychiatry, KCMH, ministry of health, Kuwait.

5-Department of rheumatology, rehabilitation and physical medicine, Benha University, Egypt

In correspondence to: Noha Maher Abdelnaser. Department of rheumatology, rehabilitation and physical medicine, Benha University

E-mail: nohamaher70@gmail.com

**ABSTRACT:**

**Background**: Patients with rheumatoid arthritis (RA) are more susceptible for having psychological comorbidities than the normal population. This is due to many factors like pain, disability, and social impacts of the arthritis besides other metabolic co-factors like vitamin D deficiency. **Purpose**: To study the link between vitamin D level as a co-factor in mood changes outcome in RA patients and the extent of mood change variables affection as well as the relation to disease activity. **Patients and Methods**: This study included 100 adult RA patients divided into two groups; Group1(G1): RA patients with low vitamin D level and Group 2(G2):RA patients with normal vitamin level, both groups were subjected to assessment of mood change and disease activity. **Results**: This study found that total Beck scale for depression and mood change variables were significantly different between the two groups (p < 0.001). Significant correlation was also found between vitamin D level and total Beck scale and mood changes (P,0.001). Disease activity index was in reverse correlation with vitamin D level in total patients’ sample (r = - 0.143), but no significant difference was found between both groups (p = 0.139). **Conclusion**: Patients with rheumatoid arthritis who have vitamin D deficiencies are more prone to exhibit psychological and mood disorders regardless the status of disease activity.

**KEYWORDS**: Rheumatoid Arthritis, Vitamin D, Mood Changes, Rheumatoid Arthritis Disease Activity Score, Beck Scale.

**INTRODUCTION:**

Rheumatoid arthritis is an autoimmune disease of undefined etiology, it is one of the most famous and common autoimmune inflammatory arthritis over the world affecting nearly 1% of the population, it primarily affects the joints, yet multiple extra-articular manifestations can be representing serious comorbidity. (1)

Mood changes are among the most common comorbidities in patients with rheumatoid arthritis and other inflammatory arthritis diseases. The incidence of a depressive disorder in RA is about 10 % - 42%. (2)

Psychological comorbidity adversely affects the outcomes in rheumatoid arthritis (RA). Mood changes, with RA, for example, might be associated with higher risk of incidental myocardial infarction, poor quality of life, and increased mortality. (3)

 Vitamin D is a hormone synthetized in human skin under the stimulation of ultraviolet radiation. Beside its endocrine role in bone metabolism, Vitamin D has immunomodulatory effects which emphasizes on the immune system including the enhancement of microbicidal ability of monocytes/macrophages and the down-modulation of inflammatory cytokines produced by T lymphocytes. Vitamin D deficiency is involved in many health problems, including immune-mediated diseases such as autoimmune disorders. (4)

Vitamin D displays an immunologic effect which can modulate the function of Th17 -related cytokines and thereby prevent perpetuation of inflammation in chronic disorders like rheumatoid arthritis. (5) Interestingly, a possible association between depression and low vitamin D levels has been found in people with gout, chronic spinal cord injuries, stroke, and multiple sclerosis raising the susceptible role of the vitamin D in the joints and neurological health. (6,7)

 People with mood changes were found to have low circulating levels of Vitamin D in their blood. So, vitamin D deficiency may be linked to an increased risk or severity of depression. (8)

The importance of vitamin D to many brain processes including neuro-immunomodulation and neuroplasticity suggests that it might have a role in psychiatric illnesses such as mood changes and depression. (9)

The biological plausibility of the association between vitamin D and depressive illness has been strengthened by the identification of vitamin D receptors in areas of the brain implicated in depression. (10)

**PATIENTS AND METHODS:**

**Objectives of the study:**

This study aimed to study the correlation between vitamin D deficiency and mood changes, especially depression, in RA patients and its relationship with disease activity.

 **Study design:**

This study is a prospective randomized clinical study of 100 adult patients of RA. The study was conducted on rheumatology clinics of Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia. From February 2017 till July 2019.

**Target population:**

-Study was conducted on 100 adults RA patients diagnosed according to American college of rheumatology /European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis classifications criteria. (11)

-Disease activity of the RA was estimated according to Disease Activity Score 28(DAS 28). (12)

-All patients were subjected to BECK depression inventory score scale which is self -scored questionnaire consists of 21 items of variable mood changes, 6 items of them were chosen according to the most commonly affected items in RA patients experienced in our clinics, each has score from 0-3 . The chosen items were (sadness, discouraged about future, irritability, dissatisfaction, sleep disturbance and fatigability). (13)

-All patients were subjected to full history taking, clinical examination and laboratory tests: Erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-citrullinated cyclic peptides (anti-CCP).

-All patients were subjected to quantitative serum vitamin D level estimated by radioimmunoassay method, considering the deficiency level is less than 30 mmol/L and the normal level is above 30 mmol/L.

**-**The patients were divided into 2 groups:

Group 1: consisted of 50 RA patients with low vitamin D level.

Group 2: consisted of 50 RA patients with normal vitamin D level.

**Inclusion criteria:**

-Age18 years and above.

-RA patients who are under treatment with disease modifying antirheumatic drugs (DMARDs) and/or biological treatment.

**Exclusion criteria:**

-Age below 18.

-Overlapped other autoimmune disorders.

-Other chronic longstanding illness.

-Current use of antidepressants medications.

-Current use of vitamin D supplements.

-Pregnancy and breastfeeding.

**Ethical considerations:**

Written approvals permitting to the Helsinki declaration were taken from all patients before being included in this study. Local ethical committee approval NO.: DSFH-ECA-022.

**Statistical methods:**

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). Categorical data were represented as numbers and percentages. Chi-square test was applied to compare between two groups. For continuous data, they were tested for normality by the Shapiro-Wilk test. Quantitative data were expressed as mean, standard deviation. Student t-test was used to compare two groups for normally distributed quantitative variables while one way ANOVA was used for comparing the different studied groups Mann Whitney test was used to compare two groups for not normally distributed quantitative variable. Pearson coefficient was used to correlate between normally distributed quantitative variables while Spearman coefficient was used to correlate between not normally distributed quantitative variables. Significance of the obtained results was judged at the 5% level.

**RESULTS:**

This study included 100 adult RA patients age range from 22-57years, G1 mean was (40.2+9) and G2 mean was (40.2+8.9) with 63 females (66% in G1 and 60% in G2) and 37 males (34% in G.1 and 40% in G2). They were divided into 50 patients with low vitamin D (G1) with mean level of (14.2+5.5) and 50 with normal vitamin D (G2) with mean level of (34.3+10.1)

Baseline demographics and characteristics were balanced between both groups for: age, sex, duration of illness with mean in G1 was (6.96+4.21) and (6.64+4.20) in G2, DAS score means were (3.3+0.9) in G1 and (3+0.8) in G2. Other parameters including RF, anti-CCP, ESR, total Beck scale and chosen variables of mood change were also studied for both groups. Significant relations were found as regards level of vitamin D (Figure 1) and total Beck scale (Figure 2) between both groups. While no significant relations were exhibited as regards DAS score (Figure 3) or other parameters. (Table 1)

When both groups were compared according to the variables of mood changes (Figure 4), significant relations were found as regards sadness, discouragement about future, irritability, dissatisfaction, and fatigability (p <0.001). While no significance (p=0.559) as regard the sleep disturbance. (Table 2)

A highly significant inverse relation was found between vitamin D level and total Beck scale (Figure 5), sadness, irritability, dissatisfaction, and fatigability (p<0.05), while no significance was significant with discouragement about future and sleep disorder in total sample patients. (Figure 6)

When we studied the correlation between vitamin D level and disease activity score in total sample, a reverse relation was encountered but no significance was found (p=0.157). (Figure 7). As regards the laboratory tests reverse correlation and high significance were found only with the level of anti-CCP (p<0.001). (Table 3)

The relation of vitamin D level and DAS score degrees were studied (Figure 8). No significant relation to degree of disease activity was found for the group of patients with low vitamin D, while it was significant with patients with normal vitamin D level. (Table 4)

Most of the patients in the studied total sample and in G1 had a mild degree of disease activity. When disease activity was correlated with Beck scale a significant relation was found with the total sample (p=0.004) and G.2 (p=0.003), but no significant relation was found in G.1(p=0.098) (Table 5).

Study of the difference between both sexes in total sample group as regards: the vitamin D level ,total Beck scale score and DAS score ,showed significant result in the total Beck scale only (P<0.001)with mean in males(32.5 ± 8.9) and in females was(24.7 ± 10.3) .Whereas , there was male predominance regarding both the lower vitamin D level, mean in males was (22.4 ± 15.3) and in females was( 22.8 ± 15.8),and higher DAS score, mean in males was( 3.3 ± 1)and in females was (3.1 ± 0.7), but with no significant differences .(Table 6)

**DISCUSSION:**

RA is an autoimmune rheumatic disorder which not only has articular manifestations, but also, extra-articular ones that can represent the most serious illness outcomes during the patient’s long-life duration. (14)

Depression and, generally, mood changes are coincident extra -articular assaults affecting high percentage of chronically ill patients including rheumatic disease, where it represents about 14-48% of total RA patients. (15)

Whether or not vitamin D level is impacting the RA disease activity or the disease severity, it is well established by many studies that vitamin D deficiency is linked to psychological health and wellbeing in normal population. The relation between the vitamin D level and mood changes disorders is growing with many trials for therapeutic efficacy of vitamin D on the mental health. (16)

In many studies there were differences in vitamin D level as regards age and sex, extreme age and females in childbearing period were found to have the lowest level of vitamin D which could be explained by the social life, education and the multiple pregnancies and giving birth. (17) While our study showed no significance as regards age or sex in both groups. Nevertheless, the vitamin D level was surprisingly lower in males than females which agrees with another study showing the same findings. (18)

Significant result was found in having more depression and mood changes in males than females which disagreed with researchers who found that females are twice more prone to develop depression than males. (19)

Besides, there was no significant difference between the two groups for the duration of illness, the laboratory indicators, or the disease activity score. While the DAS score was higher in group 1 than group 2 which can explain the effect of vitamin D deficiency on the RA outcome expression indicated by the higher DAS score in the group with low vitamin D. These findings agreed with another research which showed that vitamin D supplementation in RA active patients might improve the disease activity and severity. (20)

On the other hand, the correlation of vitamin D level with the laboratory results showed significance only with anti-CCP. Coincident findings with others who claimed the connection between the immune response parameters and vitamin D role and those who found positive relation with the anti-CCP as well. (21,22)

The link between the vitamin D deficiency in RA patients in both groups found that there was high significance between low vitamin D and the psychological parameters in the form of total Beck scale and most of the mood change variables (except for the sleep disturbance). (23) While the group which had normal vitamin D showed better psychological performance and impact. Many authors and studies established the same findings in normal population on one side and autoimmune disorders, including RA patients, on the other side. (24-26)

In the same context, the low vitamin D correlated significantly with sadness, irritability, dissatisfaction, and fatigability variables denoting that the vitamin D is correlated with the mood changes and psychological wellbeing. This agrees with other studies which linked depression, anxiety, and suicidal attempts with the vitamin D level changes. The status would be higher incidence if associated with chronic illness as RA. (27)

Interestingly, we did not find significant correlation between the vitamin D level and sleep disturbance or the discouragement about future parameters of patients in both groups which disagrees with others who found that sleep pattern is affected in patients who have low vitamin D level. (28,29)

The relation between degrees of disease activity outcome was not established to have significance with low vitamin D rather than the disease course itself. When the vitamin D level correlated with the DAS score in group 1 who has low vitamin D, negative correlation was encountered but with no significance. In agreement with other study found the same but did not prove the significant relation claiming that no correlation between serum vitamin D level and disease activity or functional ability. (30) Other authors found that the relation of vitamin D level and vitamin D insufficiency correlates inversely with RA activity suggesting that the vitamin D level is associated with susceptibility to RA activity. (31)

Significant relation between the depression Beck scale and disease activity was exhibited in our study in total sample patients denoting that disease activity correlated with the psychological expression in RA patients in general regardless the vitamin D level. (32)

**CONCLUSION:**

Ourstudy concluded that vitamin D correlates with the psychological outcome and mood changes in RA patients, while the relation with the disease activity was not proven and might need wide scale meta-analysis study in different country. More therapeutic trials are recommended to study the effect of vitamin D supplementation on the mood changes in rheumatic diseases and on psychiatric wellbeing in general.

**LIST OF ABBREVIATIONS:**

RA: rheumatoid arthritis; Vit. D: Vitamin D.; G1: Group 1.; G2: Group 2; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; DAS: disease activity index; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; Anti-CCP: Anti-citrullinated cyclic peptides; DMARDS: Disease modifying anti rheumatic drugs.

**TABLES:**

**Table 1** Comparison between the two studied groups according to demographic data

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Group 1 (n=50)** | **Group 2 (n=50)** | **Test of sig.** | **p** |
| **Age (years)** |  |  |  |  |
| Mean ± SD. | 40.2 ± 9 | 40.2 ± 8.9 | t=0.0 | 1.000 |
| Median (Min. – Max.) | 44 (22 – 57) | 44 (24 – 55) |
| **Sex** |  |  |  |  |
| Male | 17 (34%) | 20 (40%) |  | 0.534 |
| Female | 33 (66%) | 30 (60%) |
| **Duration of illness** |  |  |  |  |
| Mean ± SD. | 6.96 ± 4.21 | 6.64 ± 4.20 | U=1182.0 | 0.635 |
| Median (Min. – Max.) | 5 (2 – 17) | 5 (2 – 17) |
| **DAS score** |  |  |  |  |
| Mean ± SD. | 3.3 ± 0.9 | 3 ± 0.8 | U=1036.0 | 0.139 |
| Median (Min. – Max.) | 3 (2.5 – 5.1) | 2.9 (1.6 – 5) |
| **RF** |  |  |  |  |
| Mean ± SD. | 32.6 ± 11.8 | 32.4 ± 11.7 | t=0.051 | 0.959 |
| Median (Min. – Max.) | 30 (14 – 55) | 30 (14 – 55) |
| **Anti-CCP** |  |  |  |  |
| Mean ± SD. | 9.17 ± 7.39 | 9.09 ± 7.28 | U=1246.0 | 0.978 |
| Median (Min. – Max.) | 8 (0.40 – 25) | 8 (0.40 – 25) |
| **ESR** |  |  |  |  |
| Mean ± SD. | 35.7 ± 10.9 | 34.3 ± 10.1 | U=1158.0 | 0.524 |
| Median (Min. – Max.) | 34 (24 – 60) | 34 (20 – 60) |
| **Vit D level** |  |  |  |  |
| Mean ± SD. | 14.2 ± 5.5 | 31.1 ± 17.7 | U=562.0\* | <0.001\* |
| Median (Min. – Max.) | 13 (5 – 24) | 24 (9 – 60) |
| **Total beck scale** |  |  |  |  |
| Mean ± SD. | 32.1 ± 7.2 | 23.1 ± 11.3 | t=4.771\* | <0.001\* |
| Median (Min. – Max.) | 33 (17 – 42) | 23 (5 – 42) |

**Notes:** SD: Standard deviation. χ2: Chi square test. U: Mann Whitney test.t: Student t-test. p: p value for comparing between the studied groups \*: Statistically significant at p ≤ 0.05. Group 1: RA patients with low vit D level. Group 2: RA patients with normal vit D level

**Abbreviations:** DAS, disease activity score. RF, rheumatoid factor. Anti-CCP, anti-citrullinated cyclic peptides. ESR, erythrocyte sedimentation rate. vit d level, vitamin D level.

**Table 2** Comparison between the two studied groups according to mood changes

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Group 1 (n=50)** | **Group 2 (n=50)** | **U** | **p** |
| **Sadness** |  |  |  |  |
| Mean ± SD. | 1.96 ± 0.78 | 1.32 ± 0.74 | 724.0\* | <0.001\* |
| Median (Min. – Max.) | 2 (1 – 3) | 1 (0 – 3) |
| **Discouraged about future** |  |  |  |  |
| Mean ± SD. | 2.2 ± 0.7 | 1.6 ± 0.6 | 682.0\* | <0.001\* |
| Median (Min. – Max.) | 2 (1 – 3) | 2 (0 – 2) |
| **Irritability** |  |  |  |  |
| Mean ± SD. | 2.4 ± 0.5 | 1.6 ± 0.9 | 662.0\* | <0.001\* |
| Median (Min. – Max.) | 2 (2 – 3) | 2 (0 – 3) |
| **Dissatisfaction** |  |  |  |  |
| Mean ± SD. | 2.3 ± 0.6 | 1.6 ± 0.8 | 604.0\* | <0.001\* |
| Median (Min. – Max.) | 2 (1 – 3) | 2 (0 – 3) |
| **Sleep disturbance** |  |  |  |  |
| Mean ± SD. | 2.3 ± 0.6 | 2.2 ± 0.7 | 1174.0 | 0.559 |
| Median (Min. – Max.) | 2 (1 – 3) | 2 (1 – 3) |
| **Fatigability** |  |  |  |  |
| Mean ± SD. | 2.5 ± 0.5 | 1.6 ± 0.6 | 362.0\* | <0.001\* |
| Median (Min. – Max.) | 3 (2 – 3) | 2 (1 – 3) |

**Notes: SD:** Standard deviation: Mann Whitney test. p: p value for comparing between the studied groups \*: Statistically significant at p ≤ 0.05. Group 1: RA patients with low vitamin D level. Group 2: RA patients with normal vitamin D level

**Abbreviations:** DAS, disease activity score. RF, rheumatoid factor. Anti-CCP, anti-citrullinated cyclic peptides. ESR, erythrocyte sedimentation rate. vit d level, vitamin D level.

**Table 3** Correlation between Vitamin D level and different parameters in

 total sample (N=100)

|  |  |
| --- | --- |
|  | **Vit D level** |
| **rs** | **p** |
| **Age (years)** | 0.137 | 0.174 |
| **Duration of illness** | -0.078 | 0.443 |
| **DAS score** | -0.143 | 0.157 |
| **RF** | 0.112 | 0.267 |
| **Anti-CCP** | -0.300\* | 0.002\* |
| **ESR** | 0.175 | 0.081 |
| **Vit D level** | 1.000 | – |
| **Total Beck scale** | -0.695\* | <0.001\* |
| **Sadness** | -0.305\* | 0.002\* |
| **Discouraged about future** | 0.004 | 0.971 |
| **Irritability** | -0.298\* | 0.003\* |
| **Dissatisfaction** | -0.279\* | 0.005\* |
| **Sleep disturbance** | -0.003 | 0.976 |
| **Fatigability** | -0.249\* | 0.012\* |

**Notes:** r: Pearson coefficient.rs: Spearman coefficient. \*: Statistically significant at p ≤ 0.05

**Table 4** Relation between Vitamin D level and DAS score in each group and total sample

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DAS score** | **N** | **Vitamin D level** | **H** | **p** |
| **Mean ± SD.** | **Median (Min. – Max.)** |
| **Total sample (n=100)** |  |  |  |  |  |
| ≤2.6 (Remission) | 30 | 25.9 ± 16.3 | 19 (10 – 60) | 2.932 | 0.231 |
| >2.6 – <3.2 (Mild) | 40 | 18.1 ± 11.3 | 15 (8 – 54) |
| >3.2 – <5.1 (Moderate) | 30 | 25.5 ± 18.3 | 22 (5 – 60) |
| **Group 1 (n=50)** |  |  |  |  |  |
| ≤2.6 (Remission) | 12 | 15 ± 3.9 | 15 (10 – 19) | 1.390 | 0.499 |
| >2.6 – <3.2 (Mild) | 22 | 14.5 ± 5.1 | 13 (8 – 22) |
| >3.2 – <5.1 (Moderate) | 16 | 13.3 ± 7.1 | 12 (5 – 24) |
| **Group 2 (n=50)** |  |  |  |  |  |
| ≤2.6 (Remission) | 18 | 33.2 ± 17.4 | 38 (12 – 60) | 6.803\* | 0.033\* |
| >2.6 – <3.2 (Mild) | 18 | 22.3 ± 15.1 | 19 (9 – 54) |
| >3.2 – <5.1 (Moderate) | 14 | 39.6 ± 17.1 | 45 (9 – 60) |

**Notes**: SD: Standard deviation: F for One way ANOVA test. p: p value for comparing between DAS score categories. \*: Statistically significant at p ≤ 0.05

**Abbreviations:** DAS: disease activity index. N: number

**Table 5** Relation between total Beck scale and DAS score in each group and total sample

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DAS score** | **N** | **Total Beck scale** | **F** | **p** |
| **Mean ± SD.** | **Median (Min. – Max.)** |
| **Total sample (n=100)** |  |  |  |  |  |
| ≤2.6 (Remission) | 30 | 22.7 ± 13.8 | 17 (5 – 42) | 5.831\* | 0.004\* |
| >2.6 – <3.2 (Mild) | 40 | 30.9 ± 3.8 | 32 (20 – 35) |
| >3.2 – <5.1 (Moderate) | 30 | 28.2 ± 11.1 | 26 (8 – 42) |
| **Group 1 (n=50)** |  |  |  |  |  |
| ≤2.6 (Remission) | 12 | 29.2 ± 12.4 | 29 (17 – 42) | 2.445 | 0.098 |
| >2.6 – <3.2 (Mild) | 22 | 31.6 ± 2.2 | 32 (28 – 35) |
| >3.2 – <5.1 (Moderate) | 16 | 35 ± 6 | 37 (25 – 42) |
| **Group 2 (n=50)** |  |  |  |  |  |
| ≤2.6 (Remission) | 18 | 18.33 ± 13.33 | 12 (5 – 42) | 6.439\* | 0.003\* |
| >2.6 – <3.2 (Mild) | 18 | 29.89 ± 4.96 | 32 (20 – 35) |
| >3.2 – <5.1 (Moderate) | 14 | 20.43 ± 10.55 | 18 (8 – 40) |

**Notes**: SD: Standard deviation: F for One way ANOVA test. p: p value for comparing between DAS score categories. \*: Statistically significant at p ≤ 0.05

**Table 6** Relation between Sex and different parameters in total sample

|  |  |  |  |
| --- | --- | --- | --- |
|  | Sex | Test of sig. | p |
| **Male**  | **Female**  |
| Total sample (n=100) | **(n=37)** | **(n=63)** |  |  |
| Vit D level |  |  |  |  |
| Mean ± SD. | 22.4 ± 15.3 | 22.8 ± 15.8 | U=1160.50 | 0.971 |
| Median (Min. – Max.) | 19 (7 – 60) | 19 (5 – 60) |
| Total beck scale |  |  |  |  |
| Mean ± SD. | 32.5 ± 8.9 | 24.7 ± 10.3 | t=3.792\* | <0.001\* |
| Median (Min. – Max.) | 34 (12 – 42) | 26 (5 – 42) |
| DAS score |  |  |  |  |
| Mean ± SD. | 3.3 ± 1 | 3.1 ± 0.7 | U=1146.50 | 0.892 |
| Median (Min. – Max.) | 2.8 (1.6 – 5.1) | 3 (1.8 – 4.7) |

**Notes:** SD: Standard deviation U: Mann Whitney test t: Student t-test

p: p value for comparing between DAS score categories\*: Statistically significant at p ≤ 0.05

**FIGURE LEGANDS:**

****

 **Figure 1** Comparison between the two studied groups according to Vitamin D level



 **Figure 2** Comparison between the two groups according to total Beck scale score

** Figure 3** Comparison between the two groups according to DAS score



 **Figure 4** Comparison between the two groups according to mood changes

****

 **Figure 5a** Correlation between Vitamin D level and DAS score in total sample

******

**Figure 5b** Correlation between Vitamin D level and Total beck scale in total sample

****

 **Figure 5c** Correlation between Vitamin D level and different mood parameters in total sample.

 ****

 **Figure 6** Relation between vitamin D level and DAS score in each group and total sample.

**REFERENCES:**

1. Conforti A., di Cola I., Pavlych V., Ruscitti P., Berardicurti O., et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmune. Rev. 2021; 20:102735. Doi: 10.1016/j.autrev.2020.102735.
2. Faith Matcham, Laureen Rayner, Matthew Hotopf. the prevalence of depression in rheumatoid arthritis: a systemic review and meta-analysis. Rheumatology (Oxford)2013Dec;52(12); 213648.doi:10.1093/rheumatology/ket169.
3. Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, et al. Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity. J Rheumatol 2006; 33:1488–95.
4. Larissa Lumi, Watanabe Ishikawa, Priscila Maria Colavite, et al . Vit D deficiency and rheumatoid arthritis. Clin Rev Allergy Immunol. 2017 Jun;52(3): 373-388.doi: 10.1007/s12016-016-8577-0
5. [Behzad Heidari](https://mjrheum.org/302/newsid792/175/query/behzadheidari/modules/a%3A1%3A%7Bs%3A8%3A%22Articles%22%3Ba%3A1%3A%7Bi%3A0%3Bs%3A5%3A%22issue%22%3B%7D%7D/queryoptions/a%3A2%3A%7Bs%3A4%3A%22type%22%3Bs%3A3%3A%22tag%22%3Bs%3A10%3A%22querytitle%22%3Bs%3A14%3A%22Behzad%2BHeidari%22%3B%7D), [Karimollah Hajian-Tilaki](https://mjrheum.org/302/newsid792/175/query/karimollahhajian-tilaki/modules/a%3A1%3A%7Bs%3A8%3A%22Articles%22%3Ba%3A1%3A%7Bi%3A0%3Bs%3A5%3A%22issue%22%3B%7D%7D/queryoptions/a%3A2%3A%7Bs%3A4%3A%22type%22%3Bs%3A3%3A%22tag%22%3Bs%3A10%3A%22querytitle%22%3Bs%3A24%3A%22Karimollah%2BHajian-Tilaki%22%3B%7D), [Mansour Babaei](https://mjrheum.org/302/newsid792/175/query/mansourbabaei/modules/a%3A1%3A%7Bs%3A8%3A%22Articles%22%3Ba%3A1%3A%7Bi%3A0%3Bs%3A5%3A%22issue%22%3B%7D%7D/queryoptions/a%3A2%3A%7Bs%3A4%3A%22type%22%3Bs%3A3%3A%22tag%22%3Bs%3A10%3A%22querytitle%22%3Bs%3A14%3A%22Mansour%2BBabaei%22%3B%7D). Vitamin D Deficiency and Rheumatoid Arthritis: Epidemiological, Immunological, Clinical and Therapeutic Aspects. Mediterr J Rheumatol 2019;30(2):94-102
6. [Qiang Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+Q&cauthor_id=30679908), [Yi-Chuan Shao](https://pubmed.ncbi.nlm.nih.gov/?term=Shao+YC&cauthor_id=30679908), [Zheng-Qi Gan](https://pubmed.ncbi.nlm.nih.gov/?term=Gan+ZQ&cauthor_id=30679908), [Li-Shu Fang](https://pubmed.ncbi.nlm.nih.gov/?term=Fang+LS&cauthor_id=30679908). Lower vitamin D levels are associated with depression in patients with gout. Neuropsychiatry Dis Treat. 2019 Jan 14; 15:227-231. Doi: 10.2147/NDT. S193114. collection 2019.
7. [Khalid El-Salem](https://pubmed.ncbi.nlm.nih.gov/?term=El-Salem+K&cauthor_id=33422916), [Hanan Khalil](https://pubmed.ncbi.nlm.nih.gov/?term=Khalil+H&cauthor_id=33422916), [Alham Al-Sharman](https://pubmed.ncbi.nlm.nih.gov/?term=Al-Sharman+A&cauthor_id=33422916), [Abdel-Hameed Al-Mistarehi](https://pubmed.ncbi.nlm.nih.gov/?term=Al-Mistarehi+AH&cauthor_id=33422916). Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis. Mult Scler Relat Disorder 2021 Feb; 48:102732. Doi: 10.1016/j.msard.2020.102732. Epub 2021 Jan 2
8. Jonas BS, Mussolino ME. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med. 2000; 62:463–71
9. [Sok Kuan Wong](https://pubmed.ncbi.nlm.nih.gov/?term=Wong+SK&cauthor_id=28914205), [Kok-Yong Chin](https://pubmed.ncbi.nlm.nih.gov/?term=Chin+KY&cauthor_id=28914205), [Soelaiman Ima-Nirwana](https://pubmed.ncbi.nlm.nih.gov/?term=Ima-Nirwana+S&cauthor_id=28914205).Vitamin D and Depression: The Evidence from an Indirect Clue to Treatment Strategy. Curr Drug Targets. 2018;19(8): 888-897.doi: 10.2174/1389450118666170913161030.
10. Eyles, DW., Smith, S., Kinobe, R., Hewison, M., McGrath, JJ.  Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21–30.[C](http://dx.doi.org/10.1016/j.jchemneu.2004.08.006)
11. Aletaha D et al: ACR/EULAR 2010 Rheumatoid arthritis classification criteria Arthritis Reum 62:2569 2010 Sep.
12. Aletaha D et al. Remission and active disease in RA: defining criteria for disease activity states. Arthritis Rheum2005Sep: 52(9):2625-36.
13. Beck, A. T., Epstein, N., Brown, G., Steer, R. A. An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology,1988, Dec.: 56, 893–897.
14. [Manole Cojocaru](https://pubmed.ncbi.nlm.nih.gov/?term=Cojocaru%20M%5BAuthor%5D), [Inimioara Mihaela Cojocaru](https://pubmed.ncbi.nlm.nih.gov/?term=Cojocaru%20IM%5BAuthor%5D), [Isabela Silosi](https://pubmed.ncbi.nlm.nih.gov/?term=Silosi%20I%5BAuthor%5D), [Camelia Doina Vrabie](https://pubmed.ncbi.nlm.nih.gov/?term=Vrabie%20CD%5BAuthor%5D), [R Tanasescu](https://pubmed.ncbi.nlm.nih.gov/?term=Tanasescu%20R%5BAuthor%5D) .Extra-articular Manifestations in Rheumatoid Arthritis . [Maedica (Bucur).](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152850/) 2010 Dec; 5(4): 286–291. PMCID: PMC3152850 PMID: [21977172](https://pubmed.ncbi.nlm.nih.gov/21977172).
15. [Eric Fakra](https://pubmed.ncbi.nlm.nih.gov/?term=Fakra+E&cauthor_id=33932572), [Hubert Marotte](https://pubmed.ncbi.nlm.nih.gov/?term=Marotte+H&cauthor_id=33932572). Rheumatoid arthritis and depression. Joint BoneSpine. 2021Oct;88(5):105200. Doi. 10.1016/j.jbspin.2021.105200. Epub 2021 Apr 28.
16. Barnard K, Colón-Emeric. Extra skeletal effects of vitamin D in older adults: cardiovascular disease, mortality, mood, and cognition. The American Journal of Geriatric Pharmacotherapy. 2010;8(1):4-33. DOI: 10.1016/j.amjopharm.2010.02.004.
17. Najat M. H. Mohammed, Marfoua. S. Ali, Fayrouz A. Khaled, Eman K. Saadand, Safa M. Salih. Correlation between Age, Sex, and Vitamin D Deficiency Among Population in El-Beyda City. Global Scientific Journal of Biology 1 (2018) 32-36
18. Aljohara Al Quaiz, Ambreen Zaki, Mona Fouda, Nada Alyousefi. Age and gender differences in the prevalence and correlates of vitamin D deficiency. December 2018Archives of Osteoporosis 13(1):49DOI:10.1007/s11657-018-0461-5
19. Rand S Eid, Aarthi R Gopinath, Liisa A M Galea. Sex differences in depression: Insights from clinical and preclinical studies. Prog Neuropil. 2019 May; 176:86-102. Doi: 10.1016/j.pneurobio.2019.01.006. Epub 2019 Feb 2
20. Behzad Heidari, Karimollah Hajian-Tilaki, Mansour Babaei. Vitamin D Deficiency and Rheumatoid Arthritis: Epidemiological, Immunological, Clinical and Therapeutic Aspects. Mediterr J Rheumatol. 2019 Jun 29;30(2):94-102. Doi:10.31138/mjr.30.2.94
21. Muhammad M. Aslam, Peter John, Attya Bhatti, Sidrah Jahangir, M. I. Kamboh. Vitamin D as a Principal Factor in Mediating Rheumatoid Arthritis-Derived Immune Response. Biomed Res Int. 2019; 2019: 3494937,
22. Wang Y., Zhang F., Wang S. Serum vitamin D level is inversely associated with anti-cyclic citrullinated peptide antibody level and disease activity in rheumatoid arthritis patients. Archives of Rheumatology. 2016;31(1):64–70. Doi: 10.5606/ArchRheumatol.2016.5556.
23. Zhao W, Zhu DM, Li Q, Xu X, Zhang Y, et al .[Brain function mediates the association between low vitamin D and neurocognitive status in female patients with major depressive disorder .](https://pubmed.ncbi.nlm.nih.gov/35362398/)Psychol Med. 2022 Apr 1:1-14. Doi: 10.1017/S0033291722000708. Online ahead of print. PMID: 35362398
24. Anglin RES, Samaan Z, Walter SD, Sarah DM. Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. The British Journal of Psychiatry. 2013;202(2):100-107. DOI: 10.1192/bjp.bp.111.106666
25. Tong N, Zhang Y, Yang A, Dai X, Hao S. The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients. J Clin Lab Anal. 2022 Sep;36(9): e24643. Doi: 10.1002/jcla.24643. Epub 2022 Aug 9. PMID: 35944185
26. Lin M-C, Guo H-R, Lu M-C Livneh, H Lai N-S, Tsai T-Y. Increased risk of depression in patients with rheumatoid arthritis: a seven-year population-based cohort study. Clinics. 2015; 70: 91-96
27. Laura M Huiberts, Karin C H J Smolders. Effects of vitamin D on mood and sleep in the healthy population: Interpretations from the serotonergic pathway. Sleep Med Rev. 2021 Feb; 55:101379. Doi: 10.1016/j.smrv.2020.101379. Epub 2020 Sep 9
28. Qi Gao, Tingyan Kou, Bin Zhuang, Yangyang Ren, Xue Dong, et al. The Association between Vitamin D Deficiency and Sleep Disorders: A Systematic Review and Meta-Analysis. Nutrients. 2018 Oct 1;10(10):1395. Doi: 10.3390/nu10101395
29. Nevsun Inanc, Sibel Yilmaz-Oner, Meryem Can, Tuulikki Sokka, Haner Direskeneli. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis J. Rheumatol. 2014 Sep;41(9):1755-60. Doi: 10.3899/jrheum.131171
30. Punchong Hanvivadhanakul, Jirawan Singhea. The Relationship of Serum Vitamin D Level and Disease Activity in Rheumatoid Arthritis Patients. J Med Assoc Thai2017;100(Suppl.5): S107-S113.
31. Jin Lin,1 Jian Liu, Michael L. Davies, Weiqian Chen. Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis. PLoSOne. 2016;11(1): e0146351Publishedonline2016Jan11. Doi: 10.1371/journal.pone.0146351
32. Arkady T Manning-Bennett, Ashley M Hopkins, Michael J Sorich, Susanna M Proudman. The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomized controlled trials. Ther Adv Musculoskeletal Dis. 2022 Jul 22; 14:1759720X221111613. Doi: 10.1177/1759720X221111613.e collection 2022